Published in Clin J Am Soc Nephrol on February 04, 2010
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int (2011) 1.74
Pharmacotherapy of Hypertension in Chronic Dialysis Patients. Clin J Am Soc Nephrol (2016) 0.96
Targeting stem cell niches and trafficking for cardiovascular therapy. Pharmacol Ther (2010) 0.95
The interplay between CKD, sudden cardiac death, and ventricular arrhythmias. Adv Chronic Kidney Dis (2014) 0.92
Systolic blood pressure and mortality in patients on hemodialysis. Curr Hypertens Rep (2011) 0.90
Why do young people with chronic kidney disease die early? World J Nephrol (2014) 0.87
Impact of race on cumulative exposure to antihypertensive medications in dialysis. Am J Hypertens (2012) 0.86
Sudden Cardiac Death Among Hemodialysis Patients. Am J Kidney Dis (2017) 0.78
Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle tracking strain rate analysis: prevalence and determinants. Int J Nephrol (2012) 0.78
Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy. World J Nephrol (2015) 0.78
Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis. Nat Rev Nephrol (2016) 0.76
Antihypertensive medications and risk of death and hospitalizations in US hemodialysis patients: Evidence from a cohort study to inform hypertension treatment practices. Medicine (Baltimore) (2017) 0.75
Diagnosis and Management of Cardiovascular Disease in Advanced and End-Stage Renal Disease. J Am Heart Assoc (2016) 0.75
Angiotensin Receptor Blockers Decrease the Risk of Major Adverse Cardiovascular Events in Patients with End-Stage Renal Disease on Maintenance Dialysis: A Nationwide Matched-Cohort Study. PLoS One (2015) 0.75
Cardiovascular impact in patients undergoing maintenance hemodialysis: Clinical management considerations. Int J Cardiol (2017) 0.75
Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet (1999) 37.76
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med (2005) 12.72
Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA (2007) 5.31
Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet (2009) 4.73
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88
Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int (1995) 3.70
Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol (2001) 2.60
Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int (1989) 2.55
The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol (1999) 2.48
Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis (2008) 2.39
Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant (1996) 2.21
Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis--a randomized study. Nephrol Dial Transplant (2006) 2.11
Excerpts from the United States Renal Data System 2007 annual data report. Am J Kidney Dis (2008) 2.01
Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int (2006) 1.74
The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci (2003) 1.34
Review of aldosterone- and angiotensin II-induced target organ damage and prevention. Cardiovasc Res (2004) 1.20
Risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J Am Soc Nephrol (1994) 1.16
Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation (1994) 1.11
Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis. Am J Hypertens (1999) 0.95
Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int (1993) 0.94
Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients. J Am Soc Nephrol (1997) 0.92
Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis (2002) 0.89
Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis (1997) 0.89
Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron (2002) 0.89
Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res (2006) 0.86
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in peritoneal dialysis: systematic review and meta-analysis of randomized controlled trials. Perit Dial Int (2009) 0.86
Angiotensin receptor antagonist regresses left ventricular hypertrophy associated with diabetic nephropathy in dialysis patients. J Cardiovasc Pharmacol (2004) 0.84
Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis (2006) 0.83
Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care (2008) 0.83
Angiotensin converting enzyme inhibition for cardiac hypertrophy in patients with end-stage renal disease: what is the evidence? Nephrology (Carlton) (2004) 0.77
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Relation between kidney function, proteinuria, and adverse outcomes. JAMA (2010) 8.26
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int (2011) 6.21
Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet (2012) 5.65
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA (2007) 5.31
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet (2012) 5.10
Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med (2006) 4.90
Recommendations on screening for breast cancer in average-risk women aged 40-74 years. CMAJ (2011) 4.68
Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis (2010) 4.28
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet (2012) 4.25
Health Effects of Overweight and Obesity in 195 Countries over 25 Years. N Engl J Med (2017) 3.90
When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int (2009) 3.70
The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials (2002) 3.62
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 3.62
Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis (2003) 3.60
Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation (2004) 3.56
Recommendations on screening for type 2 diabetes in adults. CMAJ (2012) 3.51
Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. Ann Intern Med (2011) 3.49
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet (2013) 3.44
Recommendations on screening for cervical cancer. CMAJ (2013) 3.32
Intensive and Standard Blood Pressure Targets in Patients With Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis. Arch Intern Med (2012) 3.26
Early recognition and prevention of chronic kidney disease. Lancet (2010) 3.19
Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med (2011) 3.13
Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA (2009) 3.11
Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation (2005) 3.10
Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med (2007) 3.06
Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int (2013) 3.05
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int (2005) 3.03
Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med (2010) 2.97
Glomerular filtration rate, proteinuria, and the incidence and consequences of acute kidney injury: a cohort study. Lancet (2010) 2.95
Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int (2008) 2.88
Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol (2006) 2.84
Intensive care unit bed availability and outcomes for hospitalized patients with sudden clinical deterioration. Arch Intern Med (2012) 2.75
Validation of a case definition to define hypertension using administrative data. Hypertension (2009) 2.74
Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA (2010) 2.61
Overview of the Alberta Kidney Disease Network. BMC Nephrol (2009) 2.58
An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods. J Clin Epidemiol (2004) 2.58
Nocturnal hemodialysis does not improve overall measures of quality of life compared to conventional hemodialysis. Kidney Int (2008) 2.56
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Prevention of dialysis catheter malfunction with recombinant tissue plasminogen activator. N Engl J Med (2011) 2.48
Rates of treated and untreated kidney failure in older vs younger adults. JAMA (2012) 2.43
Efficacy of statins for primary prevention in people at low cardiovascular risk: a meta-analysis. CMAJ (2011) 2.40
Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2007) 2.38
Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int (2004) 2.37
Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol (2013) 2.34
The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J Am Coll Cardiol (2004) 2.32
Weekend hospital admission, acute kidney injury, and mortality. J Am Soc Nephrol (2010) 2.30
A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int (2004) 2.29
Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ (2013) 2.24
Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review. Am J Kidney Dis (2008) 2.24
Renal replacement therapy in patients with acute renal failure: a systematic review. JAMA (2008) 2.22
Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol (2013) 2.22